Edition:
United States

ARCA Biopharma Inc (ABIO.OQ)

ABIO.OQ on NASDAQ Stock Exchange Capital Market

2.65USD
11:40am EDT
Change (% chg)

$0.15 (+6.00%)
Prev Close
$2.50
Open
$2.55
Day's High
$2.70
Day's Low
$2.55
Volume
1,479
Avg. Vol
7,016
52-wk High
$4.29
52-wk Low
$2.10

Latest Key Developments (Source: Significant Developments)

ARCA Biopharma 2016 net loss $16.4 mln, or $1.81 per share
Tuesday, 21 Mar 2017 04:30pm EDT 

ARCA Biopharma Inc : Arca biopharma announces fiscal year 2016 financial results and provides business update . Arca biopharma inc - net loss was $16.4 million, or $1.81 per share, for 2016 compared to $11.4 million, or $1.82 per share, for 2015 .Arca biopharma - believes current cash, cash equivalents, to be sufficient to fund operations, at projected cost structure, through end of 2017.  Full Article

Arca Biopharma posts Q2 loss per share $0.43
Tuesday, 9 Aug 2016 04:30pm EDT 

Arca Biopharma Inc : Arca Biopharma announces second quarter 2016 financial results and provides business update .Q2 loss per share $0.43.  Full Article

Arca Biopharma Q1 loss per share $0.40
Wednesday, 11 May 2016 04:30pm EDT 

Arca Biopharma Inc : Arca Biopharma Inc On Genetic-Af trial says expects outcome of interim analysis in Q2 of 2017. . Arca Biopharma announces first quarter 2016 financial results and provides business update .Q1 loss per share $0.40.  Full Article

ARCA biopharma Inc announces closing of $37 mln private placement
Wednesday, 17 Jun 2015 09:00am EDT 

ARCA biopharma Inc:Says closing of private placement financing with a select group of institutional investors, including lead investor Venrock, New Enterprise Associates (NEA), funds managed by Franklin Advisers, Inc., RA Capital Management, Tekla Life Sciences Investors and other institutional investors.ARCA received net proceeds of about $34 mln from the sale of about 42 mln units at a price of $0.8805 per unit.Each unit consists of one share of ARCA's common stock and a warrant to purchase 0.40 shares of common stock with an exercise price of $0.8716.Warrants have a term of seven years and become exercisable 180-days after the closing date.  Full Article

ARCA biopharma Inc announces $37 mln private placement
Thursday, 11 Jun 2015 08:50am EDT 

ARCA biopharma Inc:Enters into a securities purchase agreement for a private placement financing.Private placement financing with a select group of institutional investors, including lead investor Venrock, New Enterprise Associates (NEA), funds managed by Franklin Advisers, Inc., RA Capital Management, Tekla Life Sciences Investors and other institutional investors.Upon the closing of the transaction, ARCA will receive net proceeds of about $34 mln from the sale of about 42 mln units at a price of $.8805 per unit.Private placement is expected to close on June 16, and is subject to the satisfaction of customary closing conditions.Plans to use the anticipated proceeds from the private placement for working capital and clinical development of bucindolol.MTS Securities, LLC, an affiliate of MTS Health Partners, acted as sole placement agent in the transaction.  Full Article

ARCA biopharma, Inc receives FDA fast track designation for Gencaro Atrial Fibrillation Development in genetically targeted heart failure population
Monday, 13 Apr 2015 08:30am EDT 

ARCA biopharma, Inc:Says U.S FDA has designated as Fast Track development program the investigation of Gencaro for prevention of atrial fibrillation/atrial flutter in a genetically modified heart failure population.Says Gencaro is it's investigational, pharmacologically unique beta-blocker and mild vasodilator.Gencaro is being evaluated as potential treatment for atrial fibrillation in a genetically-defined heart failure population in GENETIC-AF, a Phase 2B/3 adaptive design clinical trial.  Full Article

More From Around the Web

BRIEF-ARCA Biopharma 2016 net loss $16.4 mln, or $1.81 per share

* Arca biopharma announces fiscal year 2016 financial results and provides business update